垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体选择性甲状腺激素抵抗综合征1例

垂体选择性甲状腺激素抵抗(PRTH)综合征临床上极少见,主要表现为垂体对甲状腺激素不敏感,外周组织仍保留对T3的正常反应.因其临床表现与Graves病相似而常被误诊,并错误的长期用抗甲状腺药物治疗,甚至进行手术或131I治疗.     

垂体型甲状腺激素抵抗综合征的临诊应对

甲状腺激素抵抗综合征(syndrome of resistance to thyroid hormone, RTH)是一种罕见的遗传性甲状腺疾病。RTH临床表现及实验室检查异质性大,易被误诊甚至误治。本文通过对本院1例反复诊治长达6年的垂体型RTH患者相关临床资料进行回顾并汇总该病最新进展,以提高临床医生对RTH的认识...     

Thyroid hormone resistance: the role of mutational analysis

The finding of increased thyroxine (T4) and tri-iodothyronine (T3) levels in a patient with normal or increased thyroid-stimulating hormone is unexpected and presents a differential diagnosis between a thyroid-stimulating hormone-secreting pituitary adenoma, generalized resistance to thyroid hormone (RTH) and laboratory artefact. Without careful clinical and biochemical evaluation, errors may occur in patient diagnosis and treatment. In the case of RTH, mutation of the thyroid hormone receptor beta gene results in generalized tissue resistance to thyroid hormone. As the pituitary gland shares in this tissue resistance, euthyroidism with a normal thyroid-stimulating hormone is usually maintained by increased thyroid hormones. To date, we have identified eight pedigrees in New Zealand with mutations in the thyroid hormone receptor beta gene, including two novel mutations. Mutational analysis of the thyroid hormone receptor beta gene allows definitive diagnosis of RTH, potentially avoiding the need for protracted and expensive pituitary function testing and imaging. Mutational analysis also enables family screening and may help to avoid potential misdiagnosis and inappropriate treatment.     

From the Cover: A thyroid hormone receptor mutation that dissociates thyroid hormone regulation of gene expression in vivo

Resistance to thyroid hormone (RTH) is most often due to point mutations in the β-isoform of the thyroid hormone (TH) receptor (TR-β). The majority of mutations involve the ligand-binding domain, where they block TH binding and receptor function on both stimulatory and inhibitory TH response elements. In contrast, a few mutations in the ligand-binding domain are reported to maintain TH binding and yet cause RTH in certain tissues. We introduced one such naturally occurring human RTH mutation (R429Q) into the germline of mice at the TR-β locus. R429Q knock-in (KI) mice demonstrated elevated serum TH and inappropriately normal thyroid-stimulating hormone (TSH) levels, consistent with hypothalamic–pituitary RTH. In contrast, 3 hepatic genes positively regulated by TH (Dio1, Gpd1, and Thrsp) were increased in R429Q KI animals. Mice were then rendered hypothyroid, followed by graded T₃ replacement. Hypothyroid R429Q KI mice displayed elevated TSH subunit mRNA levels, and T₃ treatment failed to normally suppress these levels. T₃ treatment, however, stimulated pituitary Gh levels to a greater degree in R429Q KI than in control mice. Gsta, a hepatic gene negatively regulated by TH, was not suppressed in R429Q KI mice after T₃ treatment, but hepatic Dio1 and Thrsp mRNA levels increased in response to TH. Cardiac myosin heavy chain isoform gene expression also showed a specific defect in TH inhibition. In summary, the R429Q mutation is associated with selective impairment of TH-mediated gene repression, suggesting that the affected domain, necessary for TR homodimerization and corepressor binding, has a critical role in negative gene regulation by TH.     

甲状腺功能紊乱患者血清瘦素水平分析

目的　探讨甲状腺功能紊乱患者血清瘦素水平变化及瘦素与垂体—甲状腺轴 (PTA)的关系。方法　对 40例Graves病 (GD)、30例甲状腺机能减退症 (甲减 )患者和 2 8名健康受试者的血清瘦素 (leptin)、游离三碘甲状腺原氨酸 (FT3 )、游离甲状腺素 (FT4 )、促甲状腺激素 (TSH)、体脂百分含量 ( %BF)进行检测 ,所有受检者体重指数 (BMI) <2 5kg/m2 。结果　对照组血清瘦素浓度为 ( 5 .38± 3.11)ng/ml ,GD组为 ( 6 .0 7± 2 .93)ng/ml ,两组比较 ,差异无显著性 ,甲减组为 ( 10 .41± 4.45 )ng/ml,与对照组比较显著升高。三组血清瘦素浓度均与其 %BF显著正相关。对照组瘦素与TSH正相关 ,与FT3 、FT4 无相关关系。GD组瘦素与TSH、FT3 、FT4 无相关关系。甲减组因大多数TSH值增高超出检测范围 ,未作瘦素与之的相关性比较 ,而瘦素与FT3 、FT4 呈负相关关系。结论　甲状腺激素可能通过影响体脂含量而调节瘦素水平 ,瘦素和PTA是共同维持机体能量稳态的两个相互关联的系统。     

TSHR基因突变与亚临床型毒性多结节性甲状腺肿的相关研究

目的 探讨TSH受体(THSR)基因突变在亚临床型毒性多结节性甲状腺肿(STMG)发病中的作用。方法 9例STMG患者和9例非毒性结节性甲状腺肿(nTMG)患者．手术切除肿大的甲状腺组织．用酚-氯仿-异戊醇法提取基因组DNA，对目的基因片段进行聚合酶链反应(PCR)及DNA测序。结果 在9例STMG患者中，发现3例单碱基插入性突变．在1950位和1951似核酸之间插入了一个胞嘧啶(C)．使616位以后氨基酸发生了移码突变，9例nTMG未发生基因突变。结论 TSHR基因突变可能在STMG形成中发挥重要作用。     

甲状腺激素抵抗综合征两例报道并文献回顾

对2例甲状腺激素抵抗综合征患者的临床表现、实验室检查及治疗效果进行分析.2例均表现出生长发育迟缓,血清TT_3、FT_3升高,吸碘率降低.其中1例患者存在先天性鸟脸畸形和神经性耳聋,血清TSH升高.超生理剂量外源性甲状腺素可抑制其促甲状腺素的合成与释放,2例患者均对甲状腺素治疗有效.甲状腺激素抵抗综合征是甲状腺激素受体基凶突变相关性疾病,基因诊断是确诊本病的根本手段.     

促甲状腺激素受体胞内环基因突变与乳头状甲状腺癌发病的相关性研究

目的探讨乳头状甲状腺癌的发病与促甲状腺激素受体(TSHR)基因突变的相关性。方法采用巢氏-多聚酶联反应-单链构象多态性分析(NEST-PCR-SSCP)和DNA测序方法,对65例乳头状甲状腺癌和44例正常甲状腺组织TSHR3个胞内环基因进行检测。结果NEST-PCR-SSCP检测乳头状甲状腺癌促甲状腺激素受体(TSHR)3个胞内环未发现明显带型异常;DNA测序后,检测的第3胞内环2例对照组织和3例甲状腺癌组织TSHR2000位点碱基均由C→T,使得所编码的601位氨基酸由组氨酸(CAT)→酪氨酸(TAT)(His→Tyr),余胞内环未发现基因突变。结论乳头状甲状腺癌TSHR3个胞内环未发现基因突变,提示乳头状甲状腺癌发病与TSHR胞内环基因突变无关;5例标本601位氨基酸均为酪氨酸,考虑中国人TSHR基因可能与国外人群存在差异,TSHR2000位点碱基存在基因多态性。